profit from every $100 of sales.
$0$100
Humacyte
We have no price for Humacyte since 25 August 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.00-78.05% today
-99.7% since Oct 13, 25
1-year low $0.001-year high $0.31
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Humacyte vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Humacyte | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Humacyte's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.01
- 15.6×
- 76.4×
- –
- –
- -137.5%
- -53.8%
- 0.0%
Profitability
- -748.5%
- -5,649.2%
- -4,840.8%
- -5,554.1%
- -117.7%
- 34.6%
- -2,781.6%
- -88.3%
- -120.7%
- 3,638.2%
Growth
- +12.7%
- –
- −6.3%
- –
- +41.0%
Financial health
- -0.2×
- 5.67
- 59.6%
- -10.8×
- 3.93
- 3.32
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 868
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.09 | -0.12 | +22.2% |
| Mar 27, 2026 | -0.13 | -0.13 | +1.3% |
| Nov 12, 2025 | -0.11 | -0.15 | +26.8% |
| Aug 11, 2025 | -0.24 | -0.16 | −49.8% |
| May 13, 2025 | 0.30 | -0.19 | +255.7% |
| Sep 30, 2023 | -0.00 | – | – |
| Jun 30, 2023 | -0.00 | – | – |
| Mar 31, 2023 | -0.00 | – | – |
News
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to KnowYahoo Finance · Sep 18, 2026The newest story we have is from Sep 18, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
22No pass
Philip Fisher
69Pass
Peter Lynch
32No pass
Joel Greenblatt
2No pass
Charlie Munger
54No pass
Terry Smith
66Pass
Questions about Humacyte
Is Humacyte a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Humacyte AI analysis
What does Humacyte do?
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. It is in Biotechnology.
Does Humacyte pay a dividend?
No. Humacyte does not pay a dividend at the moment.
Who are Humacyte's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Humacyte's.
Prices: daily closes to Aug 25, 2026. Fundamentals: company reports via invest-like data.